Floatz logo

Imexon

Pancreatic Neoplasms

AmpliMed CorporationSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

382 Active assets in the Pancreatic Neoplasms cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Imexon is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
lymphoplasmacytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
Burkitt lymphomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →